- Home
- MLYS
as 09-11-2025 4:00pm EST
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 890.6M | IPO Year: | 2023 |
| Target Price: | $42.60 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.24 - $39.20 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | MLYS | Director | Sep 4 '25 | Buy | $25.50 | 1,176,470 | $29,999,985.00 | 5,456,521 | |
| AKKARAJU SRINIVAS | MLYS | Director | Sep 4 '25 | Buy | $25.50 | 588,235 | $14,999,992.50 | 588,235 | |
| Rodman David Malcom | MLYS | Chief Medical Officer | Aug 13 '25 | Sell | $12.93 | 11,365 | $146,986.95 | 92,891 |
Latest Mineralys Therapeutics Inc. News
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Mineralys Phase 2 Trial of Hypertension, Kidney Disease Drug Meets Primary Endpoint; Shares Up Pre-Bell
GlobeNewswire
3 months ago
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
MT Newswires
3 months ago
Jefferies Initiates Coverage on Mineralys Therapeutics With Hold Rating, $15 Price Target
TipRanks
4 months ago
Mineralys announces late-breaking presentation of data from Launch-HTN trial
Clinical Trials Arena
4 months ago
Mineralys reports outcomes from trial of lorundrostat for hypertension
GlobeNewswire
4 months ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
Zacks
4 months ago
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
GlobeNewswire
4 months ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
Compare MLYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.